A third-generation IMiD for MM.

نویسنده

  • Michele Cavo
چکیده

Over the past decade, increasing use of the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide and the first-inclass proteasome inhibitor bortezomib has dramatically changed the natural history of multiple myeloma (MM).2 Novel agents, initially approved for the treatment of relapsed or refractory (rel/refr) MM, are actually used up-front as part of induction therapy for both transplantand nontransplant-eligible patients, and studies are under way to evaluate their role in additional therapeutic phases, such as consolidation and maintenance.3,4 However, almost all patients treated with these new classes of agents inevitably develop drug resistance over time, and ultimately relapse. Mechanisms leading to resistance are largely unknown. Overexpression and mutation of 5-proteasome activity, and activation of Wnt/ -catenin signaling5 have recently been proposed as possibly related to refractoriness to bortezomib and lenalidomide, respectively. Patients failing bortezomib and lenalidomide have a very dismal clinical outlook, and represent an unmet medical need. Pomalidomide (CC-4047) is a new IMiD (see figure) with increased activity in vitro compared with thalidomide and lenalidomide, which exerts anti-MM effects through multiple mechanisms, including induction of apoptosis via caspase-8, reduction of proliferation, inhibition of NFB activation, reduction of stromal cell stimulatory cytokine secretion, and angiogenesis inhibition. The safety and toxicity profile of pomalidomide as a single agent in patients with rel/ refr MM was initially explored in two pilot phase 1 studies that established the maximum tolerated dose as 2 mg daily on days 1 through 28 of 28-day cycles and 5 mg on alternate days.6,7 In two subsequent studies enrolling patients with rel/refr MM after 1 to 4 prior lines of treatment, including refractoriness to lenalidomide, salvage therapy with pomalidomide at 2 mg/day was given continuously in 28-day cycles combined with low-dose dexamethasone.8,9 In one study, the overall rate of at least partial response (PR) was 63%, including 33% complete response or very good partial response (VGPR), and median progressionfree survival (PFS) was 11.6 months.8 Among patients refractory to prior lenalidomide, PR or better was seen in the 32% to 40% range, suggesting a lack of cross-resistance between lenalidomide and pomalidomide.9 These promising results provided the basis of the study designed by Lacy et al to evaluate the efficacy of two different doses of pomalidomide in patients with dual refractoriness (defined as progression on therapy or within 2 months of stopping treatment) to lenalidomide and bortezomib.1 For this purpose, 70 patients who had received a median of 6 prior therapies (range, 2-11) were enrolled in two sequential phase 2 trials of pomalidomide given continuously at a daily dose of either 4 or 2 mg of 28-day cycles along with 40 mg of dexamethasone on days 1, 8, 15, and 22. The rates of at least minimal response in the 4-mg and 2-mg cohorts were 49% and 43%, respectively, including VGPR and PR rates of 28.5% and 26%, respectively. These values of PR or better appear slightly lower than those observed in previously reported series of lenalidomiderefractory patients,8,9 a finding that reflects the more heavily pretreated population of patients enrolled in the current trial and, importantly, their dual refractoriness to both lenalidomide and bortezomib. Consistent with this interpretation, similar rates of at least PR were seen in the phase 1 and 2 portions (the latter using daily pomalidomide at 4 mg on days 1-21 of 28-day cycles) of MM-002 study that included patients who had been previously treated with bortezomib and lenalidomide and were refractory to their most recent regimen.10 In Lacy et al’s trial, responses to 2-mg and 4-mg doses of pomalidomide combined with dexamethasone were fast, from 1 to 2 months, and durable. With a median follow-up of 14 months, the median duration of response was not reached in the 2-mg cohort. Although a longer follow-up is required, the 6-month overall survival rates of 78% and 67% reported in the 2-mg and 4-mg cohorts are promising in a challenging population of patients for whom Molecular structure of IMiDs.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

LYMPHOID NEOPLASIA IMiD immunomodulatory compounds block C/EBP translation through eIF4E down-regulation resulting in inhibition of MM

Immunomodulatory derivatives of thalidomide (IMiD compounds), such as pomalidomide and lenalidomide, are highly active in multiple myeloma (MM) treatment. However, the precise mechanisms of action and resistance in MM are unresolved. Here we show that IMiD compounds down-regulate CCAAT/enhancer-binding protein(C/EBP ) resulting in abrogation of cell proliferation. Overexpression of C/EBP rescue...

متن کامل

IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.

Immunomodulatory derivatives of thalidomide (IMiD compounds), such as pomalidomide and lenalidomide, are highly active in multiple myeloma (MM) treatment. However, the precise mechanisms of action and resistance in MM are unresolved. Here we show that IMiD compounds down-regulate CCAAT/enhancer-binding protein-β (C/EBPβ) resulting in abrogation of cell proliferation. Overexpression of C/EBPβ re...

متن کامل

Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases.

Infections with cardiotrophic viruses and immune-mediated responses against the heart have been suggested to play a dominant role in the pathogenesis of idiopathic dilated cardiomyopathy (DCM). Furthermore, immune-mediated inflammatory diseases (IMIDs) may result in DCM. It has not previously been assessed whether DCM patients with and without an IMID have different prevalences and quantities o...

متن کامل

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia

Background Immunomodulatory drugs, IMid compounds, are active in Waldenström's macroglobulinemia (WM), although in a lesser extent than multiple myeloma, where it was initially developed. We hypothesized WM tumour cells might develop mechanisms of resistance, and sought to identify and describe these mechanisms. Material and Method MM and WM-derived cell lines, and Waldenström's CD19+ cells w...

متن کامل

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD, and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone...

متن کامل

Nanomagnetic organic-inorganic hybrid (CuFe2O4@Si-Imid-PMo): an efficient green catalyst for the synthesis of 2,4,5-trisubstituted imidazoles

In this research, a new magnetic nanocatalyst CuFe2O4@Si-Imid-PMo containing acidic ionic liquid based on imidazolium cation and phosphomolybdic acid anion immobilized on CuFe2O4@SiO2 magnetic nanoparticles was prepared and characterized using FT-IR, EDX, SEM, and VSM techniques. Then, the catalytic activity of CuFe2O4@Si-Imid-PMo was evaluated in the synthesis of 2,4,5-trisubstituted imidazole...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Blood

دوره 118 11  شماره 

صفحات  -

تاریخ انتشار 2011